Clinical trials: Mobilization
Pain, Postoperative
An Efficacy and Safety Study to Compare Fentanyl Ionsys and Routine Care With Intravenous (IV) Morphine Patient-controlled Analgesia (PCA) in Participants Who Have Undergone Elective Major Abdominal or Orthopedic Surgery
The purpose of this study is to evaluate the mobilization characteristics, clinical use, safety and Ease of Care (EOC) of a fentanyl Iontophoretic Transdermal Patient Controlled Analgesia (PCA) system (Ionsys) and morphine…
- Trial name
- NCT00766506
- Testing
- Fentanyl IONSYS, Morphine IV PCA
- Where
- 7 sites in United Kingdom
- Volunteers
- 108 people
- Sponsor
- Janssen-Cilag Ltd.
Diabetic Foot, Critical Limb Ischemia
A Clinical Trial on Diabetic Foot Using Peripheral Blood Derived Stem Cells for Treating Critical Limb Ischemia
The purpose of this study is to determine whether the method (implanting stem cells derived from peripheral blood after G-CSF mobilization) of treatment is safe and effective in the management of diabetic foot ischemia, the…
- Conditions
- Diabetic Foot, Critical Limb Ischemia, Leg Ulcers
- Trial name
- NCT00922389
- Testing
- will receive G-CSF and peripheral blood derived mononuclear cells, G-CSF, Standard Therapy
- Where
- India
- Volunteers
- 36 people
- Sponsor
- Beike Biotech India Pvt.ltd
Chronic Low-back Pain (cLBP), Urinary Incontinence (UI)
Effects of PEMM in Chronic Low Back Pain Women With Urinary Incontinence
Urinary incontinence (UI), Chronic low back pain (CLBP) in women are prevalent and often coexist. Multiple conditions when coexist, it leads to reduced Quality of life in turn causing physical and mental impairment.
- Conditions
- Chronic Low-back Pain (cLBP), Urinary Incontinence (UI), Pelvic External Myofascial Mobilisation, Myofascial Techniques
- Trial name
- NCT07351851
- Testing
- PEMM with Theragun, Active Comparator: Control
- Where
- Qatar
- Volunteers
- 200 people
- Sponsor
- Hamad Medical Corporation
Normal PBPC Donors
Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors
The purpose of this study is to clinically evaluate the spleen during PBPC mobilization by filgrastim in normal donors.
- Trial name
- NCT00115128
- Testing
- filgrastim
- Volunteers
- 309 people
- Sponsor
- Amgen
Lymphoma, Hodgkin's Lymphoma
Pegfilgrastim PBPC Mobilization Study
This is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of Filgrastim to mobilize…
- Conditions
- Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Hematology
- Trial name
- NCT00066092
- Testing
- pegfilgrastim 12 mg, filgrastim, pegfilgrastim 6 mg
- Volunteers
- 41 people
- Sponsor
- Amgen
Parkinson's Disease (PD)
Pilot Study of Robotic Spinal Mobilization in Parkinson's Disease
This interventional pilot study will evaluate the safety and clinical efficacy of robotic spinal mobilization in community-dwelling adults with Parkinson's Disease (PD).
- Trial name
- NCT07376122
- Testing
- BackHug Robotic Spinal Mobilization System
- Volunteers
- 30 people
- Sponsor
- Pacla Medical Limited
Multiple Myeloma
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.
- Trial name
- GENESIS (NCT03246529)
- Testing
- BL-8040 1.25 mg/kg + G-CSF
- Where
- 18 sites in United States, Germany and 3 more
- Volunteers
- 180 people
- Sponsor
- BioLineRx, Ltd.
Multiple Myeloma
Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma
Primary Objective: To determine if Multi Myeloma (MM) patients mobilized with granulocyte colony-stimulating factor (G-CSF) plus plerixafor 240 μg/kg are more likely to achieve a target number of greater than or equal to 6 x 10^6…
- Trial name
- NCT02221479
- Testing
- plerixafor GZ316455, Filgrastim
- Where
- 5 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Genzyme, a Sanofi Company
Autologous Haematopoietic Stem Cell Transplant
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients
This is a single-group treatment, phase IV, open label study to assess the mobilization efficacy and safety of plerixafor in combination with G- CSF in male and female participants from 18 to 75 years of age with multiple myeloma…
- Trial name
- NCT05087212
- Testing
- plerixafor + G-CSF
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Sanofi
Osteo Arthritis Knee
Effects of Compression Mobilization in OA Patients
The study Design was randomized control trial in which data was collected From Riphah Rehabilitation And Research Center and Pakistan Railway Hospital-IIMCT. Convenient sampling technique was used for data collection.
- Trial name
- NCT04944056
- Testing
- conventional physiotherapy, compression mobilization
- Where
- Pakistan
- Volunteers
- 39 people
- Sponsor
- Mir Arif Hussain
Peripheral Blood Stem Cell Transplantation
KRN125 for Mobilization of Hematopoietic Stem Cells
Data collection to evaluate safety and effect of hematopoietic stem cell mobilization into the peripheral blood after a single subcutaneous (SC) dose of KRN125(Pegfilgrastim)in healthy adults.
- Trial name
- NCT03993639
- Testing
- Pegfilgrastim
- Where
- Japan
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Multiple Myeloma
Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation
This study will examine whether 240 µg/kg plerixafor given alone for up to 4 days is safe and well tolerated in multiple myeloma (MM) patients.
- Trial name
- NCT00396383
- Testing
- plerixafor
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Genzyme, a Sanofi Company
Critical Illness, Post Operative Complication
Safety and Feasibility of a Self-Balancing Exoskeleton for Rehabilitation in the Thoracic Surgical Intensive Care Unit: a Pilot Trial
Patients admitted to the Intensive Care Unit (ICU) after thoracic surgery often experience complications related to immobility, such as muscle weakness, pulmonary issues, and longer recovery times.
- Conditions
- Critical Illness, Post Operative Complication, Thoracic Surgery
- Trial name
- HEART (NCT07220733)
- Testing
- Self-balancing robotic exoskeleton (Atalante X)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Wandercraft
Multiple Myeloma
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim) is better than G-CSF alone to mobilize and collect the…
- Trial name
- NCT00103662
- Testing
- Granulocyte colony-stimulating factor plus plerixafor
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 302 people
- Sponsor
- Genzyme, a Sanofi Company
Heart Failure, Cardiomyopathies
The Use of the EXCOR Active Driving Unit for Mobilization of Pediatric Patients With Ventricular Assist Device Support
The purpose of this observational study is to evaluate the performance of the Berlin Heart EXCOR Active driving unit while being used with the approved EXCOR ventricular assist device system.
- Conditions
- Heart Failure, Cardiomyopathies, Ventricular Dysfunction, Heart Diseases
- Trial name
- E-Motion (NCT04634708)
- Testing
- No intervention
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Berlin Heart GmbH
Non-Hodgkin's Lymphoma, Hodgkin's Disease
This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
The purpose of this program is to provide expanded access to plerixafor for patients with NHL, HD, or MM who are to receive treatment with an autologous peripheral stem cell transplant.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
- Trial name
- EAP (NCT00720603)
- Testing
- Plerixafor
- Sponsor
- Genzyme, a Sanofi Company
Multiple Myeloma
Exploratory Study on POL6326 in Stem Cell Mobilization
The purpose of this study is to determine whether POL6326 is safe and clinically active to mobilize hematopoietic stem cells followed by transplantation
- Trial name
- NCT01105403
- Testing
- POL6326
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Polyphor Ltd.
Autologous Stem Cell Transplantation
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts
This study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous…
- Trial name
- NCT00396331
- Testing
- G-CSF plus plerixafor
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Genzyme, a Sanofi Company
Large Reperfused ST-Elevation Myocardial Infarction
CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI)
The purpose of this study is to investigate the effects of POL6326 (CXCR4 antagonist) as a stem cell mobilizing agent, on cardiac function and infarct size and on safety and tolerability, in patients with reperfused ST-Elevation…
- Trial name
- CATCH-AMI (NCT01905475)
- Testing
- POL6326
- Where
- 17 sites in Austria, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Polyphor Ltd.
Non-Hodgkin's Lymphoma
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms
The purpose of this study was to compare the responses of 2 different doses of plerixafor in patients with Non-Hodgkin's Lymphoma (NHL) who received an autologous stem cell transplant.
- Trial name
- NCT01164475
- Testing
- Granulocyte-colony stimulating factor (G-CSF), Fixed Dose Plerixafor, Weight-Based Plerixafor
- Where
- 7 sites in United States, Canada and 2 more
- Volunteers
- 61 people
- Sponsor
- Genzyme, a Sanofi Company